These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38116160)

  • 1. Imeglimin Improved Plasma Glucose Levels in Patients With Latent Autoimmune Diabetes of Adults: Report of 2 Cases.
    Okada S; Okada K; Okada J; Yamada E
    JCEM Case Rep; 2024 Jan; 2(1):luad161. PubMed ID: 38116160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
    Johansson KS; Brønden A; Knop FK; Christensen MB
    Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Pozzilli P; Leslie RD; Peters AL; Buzzetti R; Shankar SS; Milicevic Z; Pavo I; Lebrec J; Martin S; Schloot NC
    Diabetes Obes Metab; 2018 Jun; 20(6):1490-1498. PubMed ID: 29377522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
    Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
    Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
    [No Abstract]   [Full Text] [Related]  

  • 5. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
    Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
    BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Education, immigration and income as risk factors for hemoglobin A1c >70 mmol/mol when diagnosed with type 2 diabetes or latent autoimmune diabetes in adult: a population-based cohort study.
    Martinell M; Pingel R; Hallqvist J; Dorkhan M; Groop L; Rosengren A; Storm P; Stålhammar J
    BMJ Open Diabetes Res Care; 2017; 5(1):e000346. PubMed ID: 28761648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
    Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
    Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study.
    Manisha AM; Shangali AR; Mfinanga SG; Mbugi EV
    BMC Endocr Disord; 2022 Jul; 22(1):175. PubMed ID: 35804315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus.
    Szepietowska B; Głębocka A; Puch U; Górska M; Szelachowska M
    Arch Med Sci; 2012 Jul; 8(3):491-5. PubMed ID: 22852005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent Autoimmune Diabetes in an Adult Male Presenting With Diabetic Ketoacidosis (DKA).
    Imam SK; Hassan FM; Mohamed H
    Cureus; 2023 Jan; 15(1):e33847. PubMed ID: 36819447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Hagi K; Nitta M; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latent Autoimmune Diabetes in Adults (LADA) and its Metabolic Characteristics among Yemeni Type 2 Diabetes Mellitus Patients.
    Al-Zubairi T; Al-Habori M; Saif-Ali R
    Diabetes Metab Syndr Obes; 2021; 14():4223-4232. PubMed ID: 34675573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent autoimmune diabetes in youth shows greater autoimmunity than latent autoimmune diabetes in adults: Evidence from a nationwide, multicenter, cross-sectional study.
    Cheng J; Tang X; Yan X; Huang G; Luo S; Zhou Z; Li X
    Pediatr Diabetes; 2022 Aug; 23(5):578-587. PubMed ID: 35451144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family history of type 1 and type 2 diabetes and risk of latent autoimmune diabetes in adults (LADA).
    Hjort R; Alfredsson L; Andersson T; Carlsson PO; Grill V; Groop L; Martinell M; Rasouli B; Storm P; Tuomi T; Carlsson S
    Diabetes Metab; 2017 Dec; 43(6):536-542. PubMed ID: 28669512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
    Buzzetti R; Pozzilli P; Frederich R; Iqbal N; Hirshberg B
    Diabetes Metab Res Rev; 2016 Mar; 32(3):289-96. PubMed ID: 26385269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
    Pirags V; Lebovitz H; Fouqueray P
    Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.